Luminal B breast tumors are not HER2 positive

Breast Cancer Research

Volumn 10, Issue 5, 2008, Pages

  Bhargava, Rohit ^a   Dabbs, David J ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; ESTROGEN RECEPTOR; TUMOR MARKER; TUMOR PROTEIN;

BREAST TUMOR; CHEMISTRY; CLASSIFICATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; NEOPLASM; NOTE; PAGET NIPPLE DISEASE; PROTO ONCOGENE;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; ESTROGENS; FEMALE; GENE AMPLIFICATION; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; NEOPLASM PROTEINS; NEOPLASMS, HORMONE-DEPENDENT; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 59449088407     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2134     Document Type: Letter

References (13)

1. Tamimi RM, Baer HJ, Marotti J, Galan M, Galaburda L, Fu Y, Deitz AC, Connolly JL, Schnitt SJ, Colditz GA, Collins LC. Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer. Breast Cancer Res 2008, 10:R67. 10.1186/bcr2128, 18681955.
2. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006, 295:2492-2502. 10.1001/jama.295.21.2492, 16757721.
3. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lønning P, Børresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98:10869-10874. 58566, 11553815, 10.1073/pnas.191367098.
4. Sorlie T. Molecular classification of breast tumors: toward improved diagnostics and treatments. Methods Mol Biol 2007, 360:91-114.
5. Goldstein NS, Ferkowicz M, Odish E, Mani A, Hastah F. Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma. Am J Clin Pathol 2003, 120:86-92. 10.1309/QPHDRB00QXGMUQ9N, 12866377.
6. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999, 17:1474-1481.
7. McCarty KS, Miller LS, Cox EB, Konrath J, McCarty KS. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 1985, 109:716-721.
8. Flanagan MB, Dabbs DJ, Brufsky AM, Beriwal S, Bhargava R. Histopathologic variables predict Oncotype DX™ Recurrence Score. Mod Pathol 2008,
9. Baehner FL, Maddala T, Alexander C, Gown A, Goldstein LC, Achacoso NS, Shak S, Quesenberry CP, Habel LA. A Kaiser-Permanente population-based study of ER and PR expression by the standard method, immunohistochemistry (IHC), compared to a new method, quantitative reverse transcription polymerase chain reaction (RT-PCR) [abstract 88]. ASCO Breast Cancer Symposium 2007, http://www.genomichealth.com/pressroom/postersandabstracts.aspx?FileMaterialID=38
10. Cronin M, Pho M, Dutta D, Stephans JC, Shak S, Kiefer MC, Esteban JM, Baker JB. Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. Am J Pathol 2004, 164:35-42. 1602211, 14695316.
11. Lacroix M, Querton G, Hennebert P, Larsimont D, Leclercq G. Estrogen receptor analysis in primary breast tumors by ligand-binding assay, immunocytochemical assay, and northern blot: a comparison. Breast Cancer Res Treat 2001, 67:263-271. 10.1023/A:1017946810277, 11561772.
12. Baehner FL, Watson D, Shak S, Habel LA, Quesenberry CP, Capra A, Tang G, Paik S, Wolmark N. Quantitative RT-PCR analysis of ER and PR by Oncotype DX indicates distinct and different associations with prognosis and prediction of tamoxifen benefit [abstract 45]. 29th Annual San Antonio Breast Cancer Symposium 2006, http://www.genomichealth.com/pressroom/postersandabstracts.aspx?FileMaterialID=24
13. Lal P, Salazar PA, Hudis CA, Ladanyi M, Chen B. HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2,279 cases and comparison of dual-color and single-color scoring. Am J Clin Pathol 2004, 121:631-636. 10.1309/VE7862V2646BR6EX, 15151202.